UPDATE: Piper Jaffray Initiates Coverage on Athersys
www.InvestorStemCell.com
Donate
Results 1 to 7 of 7
Like Tree3Likes
  • 2 Post By DonV
  • 1 Post By Superfeeed

Thread: UPDATE: Piper Jaffray Initiates Coverage on Athersys

  1. #1
    Experience
    Points: 7,961, Level: 60
    Level completed: 6%, Points required for next Level: 189
    Overall activity: 21.0%
    Achievements:
    SocialTagger First ClassCreated Blog entry5000 Experience PointsVeteran
    DonV's Avatar
    Join Date
    Mar 2011
    Posts
    1,209
    Location
    Texas
    Country: United States
    Blog Entries
    3
    Likes Given: 734
    Likes Received: 1545

    UPDATE: Piper Jaffray Initiates Coverage on Athersys

    UPDATE: Piper Jaffray Initiates Coverage on Athersys
    By Delores Land
    Benzinga Staff Writer
    March 20, 2012 7:26 AM

    Symbols: ATHXTags: Piper JaffrayPosted in: Analyst Color, Initiation, Analyst Ratings(less)
    Symbols: ATHX
    Tags: Piper Jaffray

    ShareAccording to a research report published earlier today, Piper Jaffray has initiated Athersys Inc. (NASDAQ: ATHX [FREE Stock Trend Analysis]) with an Overweight rating and $4 PT.

    Piper Jaffray explained in the report, “Athersys is a regenerative medicine company developing MultiStem, an offthe-shelf stem cell therapy comprised of multipotent adult progenitor cells (MAPCs). Athersys is scheduled to discuss the design of a pivotal study in graft-vs. host disease (GvHD) with the FDA in May, offering a potential fast path to market. Athersys also partnered MultiStem with Pfizer in inflammatory bowel disease (IBD) with data from a randomized Phase II study expected in 1Q:13. Beyond these indications, Athersys is developing MultiStem for stroke and heart attack. Athersys recently raised $9 million in a private placement bringing pro forma cash to ~$25 million, which should last into mid'13. Trading at an enterprise value of only $22 million, we view Athersys as an attractive regenerative medicine play with multiple shots on goal.”

    Athersys closed yesterday at $1.67.
    .

    Read more: UPDATE: Piper Jaffray Initiates Coverage on Athersys | Benzinga
    michaelbrom and dyooperya like this.

  2. #2
    Experience
    Points: 2,147,540,163, Level: 100
    Level completed: 0%, Points required for next Level: 0
    Overall activity: 18.0%
    Achievements:
    SocialRecommendation First ClassCreated Blog entryTagger First Class50000 Experience Points
    Superfeeed's Avatar
    Join Date
    Feb 2011
    Posts
    4,512
    Location
    Martha's Vineyard
    Country: United States
    Blog Entries
    21
    Likes Given: 4800
    Likes Received: 10611
    MAY FDA;; mmmmm that rymes..

    UPDATE: Piper Jaffray Initiates Coverage on Athersys
    By Delores Land
    Benzinga Staff Writer
    March 20, 2012 7:26 AM


    Symbols: ATHX
    Tags: Piper Jaffray
    Posted in: Analyst Color, Initiation, Analyst Ratings
    (less)
    Symbols: ATHX
    Tags: Piper Jaffray
    Posted in: Analyst Co (…more)





    Share





    According to a research report published earlier today, Piper Jaffray has initiated Athersys Inc. (NASDAQ: ATHX[FREE Stock Trend Analysis]) with an Overweight rating and $4 PT.
    Piper Jaffray explained in the report, “Athersys is a regenerative medicine company developing MultiStem, an offthe-shelf stem cell therapy comprised of multipotent adult progenitor cells (MAPCs). Athersys is scheduled to discuss the design of a pivotal study in graft-vs. host disease (GvHD) with the FDA in May, offering a potential fast path to market. Athersys also partnered MultiStem with Pfizer in inflammatory bowel disease (IBD) with data from a randomized Phase II study expected in 1Q:13. Beyond these indications, Athersys is developing MultiStem for stroke and heart attack. Athersys recently raised $9 million in a private placement bringing pro forma cash to ~$25 million, which should last into mid'13. Trading at an enterprise value of only $22 million, we view Athersys as an attractive regenerative medicine play with multiple shots on goal.”
    Athersys closed yesterday at $1.67.




    Read more: UPDATE: Piper Jaffray Initiates Coverage on Athersys | Benzinga
    Give me a firm place to stand, and I will move the earth.
    Archimedes

  3. #3
    Experience
    Points: 21,863, Level: 92
    Level completed: 52%, Points required for next Level: 487
    Overall activity: 37.0%
    Achievements:
    SocialTagger First Class10000 Experience PointsVeteran
    Awards:
    Calendar Award
    michaelbrom's Avatar
    Join Date
    Apr 2011
    Posts
    2,360
    Location
    Houston
    Country: United States
    Likes Given: 7690
    Likes Received: 3334
    very nice

  4. #4
    Experience
    Points: 7,961, Level: 60
    Level completed: 6%, Points required for next Level: 189
    Overall activity: 21.0%
    Achievements:
    SocialTagger First ClassCreated Blog entry5000 Experience PointsVeteran
    DonV's Avatar
    Join Date
    Mar 2011
    Posts
    1,209
    Location
    Texas
    Country: United States
    Blog Entries
    3
    Likes Given: 734
    Likes Received: 1545
    JV only wish haha

  5. #5
    Experience
    Points: 367, Level: 7
    Level completed: 34%, Points required for next Level: 33
    Overall activity: 9.0%
    Achievements:
    Tagger Second Class250 Experience Points3 months registered
    wasteoftime's Avatar Associate Member
    Join Date
    Mar 2012
    Posts
    22
    Country: United States
    Likes Given: 1
    Likes Received: 18
    Does $4 seem low to anyone else?

  6. #6
    Experience
    Points: 2,147,540,163, Level: 100
    Level completed: 0%, Points required for next Level: 0
    Overall activity: 18.0%
    Achievements:
    SocialRecommendation First ClassCreated Blog entryTagger First Class50000 Experience Points
    Superfeeed's Avatar
    Join Date
    Feb 2011
    Posts
    4,512
    Location
    Martha's Vineyard
    Country: United States
    Blog Entries
    21
    Likes Given: 4800
    Likes Received: 10611
    Quote Originally Posted by wasteoftime View Post
    Does $4 seem low to anyone else?
    I like it. Very conservative. ATHX is on nobodys Radar.
    Give me a firm place to stand, and I will move the earth.
    Archimedes

  7. #7
    Experience
    Points: 2,147,540,163, Level: 100
    Level completed: 0%, Points required for next Level: 0
    Overall activity: 18.0%
    Achievements:
    SocialRecommendation First ClassCreated Blog entryTagger First Class50000 Experience Points
    Superfeeed's Avatar
    Join Date
    Feb 2011
    Posts
    4,512
    Location
    Martha's Vineyard
    Country: United States
    Blog Entries
    21
    Likes Given: 4800
    Likes Received: 10611
    Quote Originally Posted by DonV View Post
    UPDATE: Piper Jaffray Initiates Coverage on Athersys
    By Delores Land
    Benzinga Staff Writer
    March 20, 2012 7:26 AM

    Symbols: ATHXTags: Piper JaffrayPosted in: Analyst Color, Initiation, Analyst Ratings(less)
    Symbols: ATHX
    Tags: Piper Jaffray

    ShareAccording to a research report published earlier today, Piper Jaffray has initiated Athersys Inc. (NASDAQ: ATHX [FREE Stock Trend Analysis]) with an Overweight rating and $4 PT.

    Piper Jaffray explained in the report, “Athersys is a regenerative medicine company developing MultiStem, an offthe-shelf stem cell therapy comprised of multipotent adult progenitor cells (MAPCs). Athersys is scheduled to discuss the design of a pivotal study in graft-vs. host disease (GvHD) with the FDA in May, offering a potential fast path to market. Athersys also partnered MultiStem with Pfizer in inflammatory bowel disease (IBD) with data from a randomized Phase II study expected in 1Q:13. Beyond these indications, Athersys is developing MultiStem for stroke and heart attack. Athersys recently raised $9 million in a private placement bringing pro forma cash to ~$25 million, which should last into mid'13. Trading at an enterprise value of only $22 million, we view Athersys as an attractive regenerative medicine play with multiple shots on goal.”

    Athersys closed yesterday at $1.67.
    .

    Read more: UPDATE: Piper Jaffray Initiates Coverage on Athersys | Benzinga
    So the P&J peaked my interest inregards to the FDA meeting in May. so much so I wrote P&J and told them to take another look. MultiStem: A Novel Stem Cell Therapy

    This FDA May meeting may reshape everything from BMT's to Universal Blood. Incredibly interesting and huge immediate revenue potential...

    MultiStem: A Novel Stem Cell Therapy
    We are developing MultiStem®, a proprietary stem cell product for the treatment of multiple distinct diseases and conditions in the cardiovascular, neurological, inflammatory and immune disease areas. MultiStem is a biologic product that is manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources. Unlike other cell types, after isolation from a qualified donor MultiStem may be expanded on a large scale for future clinical use and stored in frozen form until needed. Cells obtained from a single donor require no genetic modification and may be used to produce banks yielding hundreds of thousands to millions of doses of MultiStem – an amount far greater than other stem cell types can achieve. Each bank is extensively characterized to ensure product consistency and safety.
    MultiStem consists of a special class of human stem cells that have the ability to express a range of therapeutically relevant proteins and other factors, as well as form multiple cell types. Factors expressed by MultiStem have the potential to deliver a therapeutic benefit in several ways, such as reducing inflammation, protecting damaged or injured tissue, and enhancing the formation of new blood vessels in regions of ischemic injury. These cells exhibit a drug-like profile in that they act primarily through the production of multiple factors that regulate the immune system, protect damaged or injured cells, promote tissue repair and healing, and the cells are subsequently cleared from the body over time.
    During several years of preclinical work, MultiStem has demonstrated the potential to address each of the fundamental limitations observed with traditional bone marrow or hematopoietic stem cell transplants. These limitations include the historical requirement for tissue matching between donor and patient, the typical need for one donor for each patient (a reflection of the inability to expand cells in a controlled and reproducible manner), frequent use of immune suppressive drugs to avoid rejection or immune system complications, and a range of other potential safety issues.
    We believe that MultiStem represents a potential best-in-class stem cell therapy because it exhibits each of the following characteristics based on research and development to date: (1) it may be produced on an industrial scale, in a well validated and reproducible manner; (2) it may be administered without tissue matching, making it analogous to type O blood; (3) it exhibits a consistent safety profile; and (4) it appears capable of delivering therapeutic benefit through multiple mechanisms of action. Based upon work that we and independent collaborators have conducted over the past several years, we believe that MultiStem has the potential to treat a range of disease indications, including ischemic injury and cardiovascular disease, certain neurological diseases, autoimmune disease, transplant support (including in oncology patients), and a range of orphan disease indications.
    Though the cells have the potential to differentiate into a variety of cell types, the primary mechanisms of action appear to be achieved through the production of a physiologically relevant and complex set of therapeutic molecules in response to the local environment. In the initial indications Athersys is pursuing, the cells appear to minimize the inflammatory reaction that occurs in response to ischemic events (such as myocardial infarction or stroke) or the anti-host immune reaction seen in graft vs. host disease (GvHD), and promote healing and recovery in other ways. Unlike traditional pharmaceuticals, MultiStem cells are dynamically regulated, and have the potential to respond to signals of inflammation or tissue damage in multiple ways. Potential mechanisms of benefit include protection of damaged or injured cells, reduction of inflammation, stimulation of new blood vessels, and the recruitment of other cell types to promote tissue repair and healing.

    MultiStem's ability to be delivered “off the shelf” like a traditional pharmaceutical is based on:

    • Scalability - The product can be produced efficiently and consistently in large quantities and stored (frozen) for subsequent use. The equivalent of millions of doses may be produced from a single healthy, consenting donor, and biological characteristics and yield are consistent across donors
    • "Off-the-shelf" administration - In contrast to conventional bone marrow or hematopoietic stem cell transplants and most other cell types, extensive preclinical studies have shown that MultiStem may be used without tissue matching, making it analogous to type “O” blood
    • Multiple approaches to delivery - MultiStem may be delivered systemically (e.g. intravenously) or via local administration (e.g. using a catheter based delivery system), depending on the disease indication and the specific needs of the patient


    MultiStem allows us to efficiently pursue multiple, high-value commercial and therapeutic opportunities from a single product platform. We are focused on developing MultiStem broadly for the treatment of ischemic injury (e.g.: myocardial infarction, stroke and other indications) and for conditions involving the immune system, such as autoimmune disease or other indications.
    EYESEE likes this.
    Give me a firm place to stand, and I will move the earth.
    Archimedes